Design and Evaluation of RNA Aptamer-Mediated Delivery of C/EBP

D Vasconcelos, M H Sodergren, V Reebye, J Vasara, M S Song, K Holm, S E Khorsandi, J Rossi, N Habib, K W Huang

Erratum issuedAbstract read

In one paragraph

Article in Journal of nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Chemical Modification Strategies for Therapeutic Oligonucleotides: Mechanism Compatibility, Design Trade-Offs, and Translational Barriers.Molecules (Basel, Switzerland) · 2026
Review
GalNAc-conjugated siRNA targeting C/EBPβ reverses metabolic dysfunction and restores liver homeostasis in a murine MASLD model.Molecular therapy. Nucleic acids · 2026
Article

4 · The record

Corrections and comments

Erratum issued
Corrigendum to "Design and Evaluation of RNA Aptamer-Mediated Delivery of C/EBP2025

5 · Who and what money

Authors and funding

10 authors.

D VasconcelosDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-7522-8964

M H SodergrenDepartment of Surgery and Cancer, Imperial College London, London, UK.

V ReebyeDepartment of Surgery and Cancer, Imperial College London, London, UK.

J VasaraDepartment of Surgery and Cancer, Imperial College London, London, UK.

M S SongDepartment of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, California, USA.

K HolmDepartment of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, California, USA.

S E KhorsandiDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-1624-4467

J RossiDepartment of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, California, USA.

N HabibDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-4920-4154

K W HuangDepartment of Surgery and Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan (ROC).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CCAAT/enhancer-binding protein beta (CEBPB or C/EBP

Identifiers

PMID40226120

DOI10.1155/jna/1461574

PMCPMC11991783

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.